Alcohol use disorder — compounds assessed

§4Compounds assessed

Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.

• DSIP in alcohol use disorder

  Endogenous nonapeptide0 contributing trialsfull monograph

  Small historical reports in withdrawal syndromes; not assessable — —

  Very low
• NAD+ (nicotinamide adenine dinucleotide) in alcohol use disorder

  Endogenous pyridine dinucleotide coenzyme0 contributing trialsfull monograph

  No assessable randomised evidence identified — Intravenous NAD+ is offered commercially for substance-withdrawal indications with no controlled evidence base.

  Very low

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.